| Literature DB >> 28060753 |
Yi Zheng1, Yun Luo2, Yinxiang Lv3, Chen Huang2, Qinsong Sheng4, Peng Zhao1, Julian Ye2, Weiqin Jiang1, Lulu Liu1, Xiaojun Song2, Zhou Tong1, Wenbin Chen4, Jianjiang Lin4, Yi-Wei Tang5, Dazhi Jin2, Weijia Fang1.
Abstract
The entire process of Clostridium difficile colonization to infection develops in large intestine. However, the real colonization pattern of C. difficile in preoperative colorectal cancer patients has not been studied. In this study, 33 C. difficile strains (16.1%) were isolated from stool samples of 205 preoperative colorectal cancer patients. C. difficile colonization rates in lymph node metastasis patients (22.3%) were significantly higher than lymph node negative patients (10.8%) (OR=2.314, 95%CI=1.023-5.235, P =0.025). Meanwhile, patients positive for stool occult blood had lower C. difficile colonization rates than negative patients (11.5% vs. 24.0%, OR=0.300, 95%CI=0.131-0.685, P =0.019). A total of 16 sequence types were revealed by multilocus sequence typing. Minimum spanning tree and time-space cluster analysis indicated that all C. difficile isolates were epidemiologically unrelated. Antibiotic susceptibility testing showed all isolates were susceptible to vancomycin and metronidazole. The results suggested that the prevalence of C. difficile colonization is high in preoperative colorectal cancer patients, and the colonization is not acquired in the hospital. Since lymph node metastasis colorectal cancer patients inevitably require adjuvant chemotherapy and C. difficile infection may halt the ongoing treatment, the call for sustained monitoring of C. difficile in those patients is apparently urgent.Entities:
Keywords: Clostridium difficile; colonization; colorectal cancer; epidemiology; transmission
Mesh:
Year: 2017 PMID: 28060753 PMCID: PMC5355311 DOI: 10.18632/oncotarget.14424
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Characteristics and risk factors of C. difficile colonization in 205 CRC patients
| Characteristic | No.(%) of patients for | Results for analysis | |||||
|---|---|---|---|---|---|---|---|
| Bivariant | Multivariant logistic | ||||||
| (n=33) | (n=172) | OR | 95% CI | ||||
| Age | <60 (n=74) | 9 (12.2) | 65 (87.8) | 0.249 | 1.560 | 0.652-3.735 | 0.318 |
| ≥60 (n=131) | 24 (18.3) | 107 (81.7) | |||||
| Site | Colon (n=91) | 15 (16.5) | 76 (83.5) | 0.893 | 0.991 | 0.397-2.474 | 0.984 |
| Rectum (n=114) | 18 (15.8) | 96 (84.2) | |||||
| Morphology | Ulcerative (n=134) | 25 (18.7) | 109 (81.3) | 0.171 | 0.744 | 0.287-1.926 | 0.242 |
| Exophytic (n=71) | 8 (11.3) | 63 (88.7) | |||||
| Differentiation | Poor (n=62) | 8 (12.9) | 54 (87.1) | 0.413 | 1.424 | 0.825-6.481 | 0.401 |
| Well (n=143) | 25 (17.5) | 118 (82.5) | |||||
| T stage | Non-T4 (n=150) | 20 (13.3) | 130 (86.7) | 0.075 | 2.301 | 0.963-5.500 | 0.061 |
| T4 (n=55) | 13 (23.6) | 42 (76.4) | |||||
| N stage | LN neg. (n=111) | 12 (10.8) | 99 (89.2) | 0.025* | 2.314 | 1.023-5.235 | 0.044* |
| LN pos. (n=94) | 21 (22.3) | 73 (77.7) | |||||
| Albumin (g/L) | <35 (n=17) | 5 (29.4) | 12 (70.6) | 0.119 | 0.315 | 0.073-1.357 | 0.121 |
| ≥35 (n=188) | 28 (14.9) | 160 (85.1) | |||||
| FBG (mmol/L) | <7.0 (n=192) | 32 (16.7) | 160 (83.3) | 0.394 | 0.337 | 0.033-3.455 | 0.360 |
| ≥7.0 (n=13) | 1 (7.7) | 12 (92.3) | |||||
| BMI | <24 (n=114) | 17 (14.9) | 97 (85.1) | 0.605 | 1.358 | 0.581-3.177 | 0.480 |
| ≥24 (n=91) | 16 (17.6) | 75 (82.4) | |||||
| TG (mmol/L) | ≥1.70 (n=38) | 6 (15.8) | 32 (84.2) | 0.954 | 1.129 | 0.497-4.703 | 0.917 |
| <1.70 (n=167) | 27 (16.2) | 140 (83.8) | |||||
| TC (mmol/L) | <5.70 (n=190) | 31 (16.3) | 159 (83.7) | 0.762 | 0.858 | 0.097-3.199 | 0.612 |
| ≥5.70 (n=15) | 2 (13.3) | 13 (86.7) | |||||
| HDL (mmol/L) | < 0.80 (n=20) | 2 (10.0) | 18 (90.0) | 0.435 | 1.768 | 0.337-9.274 | 0.500 |
| ≥ 0.80 (n=185) | 31 (16.8) | 154 (83.2) | |||||
| Hemoglobin (g/L) | <120 (n=55) | 10 (18.2) | 45 (81.8) | 0.623 | 0.911 | 0.319-2.602 | 0.861 |
| ≥120 (n=150) | 23 (15.3) | 127 (84.7) | |||||
| OB | Negative (n=75) | 18 (24.0) | 57 (76.0) | 0.019* | 0.300 | 0.131-0.685 | 0.004* |
| Positive (n=130) | 15 (11.5) | 115 (88.5) | |||||
Abbreviations: *P <0.05; LN: Lymph nodes; FBG: Fast blood glucose; BMI: Body mass index; TG: Triglyceride; TC: Total cholesterol; HDL: High density lipoprotein
Figure 1Relationships of the 33 colonizing C. difficile strains by minimum spanning tree based on MLST data
The number in the circle indicates the ST and the size of the circle corresponds the total number of isolates belonging to that ST. The number of allelic difference between STs is indicated on the branches. Nodes were connected by a dashed line if the difference is more than two alleles.
Figure 2Time-space cluster map of different STs from individual CRC patients with C. difficile colonization
Y-axis depicts unique multilocus STs. X-axis (bottom) shows the duration of the study period. Each small box represents the date of admission and the length of hospital stay of an individual C. difficile colonizing CRC patient.
Antibiotic resistance profile of 33 C. difficile strains according to pathology and demographic characteristics
| Antibiotic | No. (%) resistant | ||||||
|---|---|---|---|---|---|---|---|
| Cancer site | Age | ||||||
| Total | Rectum | Colon | P value | <60 | ≥60 | P value | |
| n=33 | n=18 | n=15 | n=9 | n=24 | |||
| Fusidic acid | 17 (51.5) | 13 (72.2) | 4 (26.7) | 0.01* | 4 (44.4) | 13 (54.2) | 0.62 |
| Ciprofloxacin | 26 (78.8) | 14 (77.8) | 12 (80.0) | 0.88 | 9 (100.0) | 17 (70.8) | 0.07 |
| Piperacillin/Tazobactam | 1 (3.0) | 1 (5.6) | 0 (0) | NA | 0 (0) | 1 (4.2) | NA |
| Metronidazole | 0 (0) | 0 (0) | 0 (0) | NA | 0 (0) | 0 (0) | NA |
| Rifampicin | 9 (27.3) | 5 (27.8) | 4 (26.7) | 0.94 | 1 (11.1) | 8 (33.3) | 0.20 |
| Moxifloxacin | 15 (45.5) | 6 (33.3) | 9 (60.0) | 0.13 | 7 (77.8) | 8 (33.3) | 0.02* |
| Gatifloxacin | 14 (42.4) | 8 (44.4) | 6 (40.0) | 0.80 | 2 (22.2) | 12 (50.0) | 0.15 |
| Vancomycin | 0 (0) | 0 (0) | 0 (0) | NA | 0 (0) | 0 (0) | NA |
| Clindamycin | 21 (63.6) | 12 (66.7) | 9 (60.0) | 0.69 | 6 (66.7) | 15 (62.5) | 0.83 |
| Levofloxacin | 22 (66.7) | 12 (66.7) | 10 (66.7) | 1.00 | 7 (77.8) | 15 (62.5) | 0.41 |
| Tetracycline | 16 (48.5) | 8 (44.4) | 8 (53.3) | 0.53 | 6 (66.7) | 10 (41.7) | 0.20 |
| Erythromycin | 21 (63.6) | 11 (61.1) | 10 (66.7) | 0.74 | 8 (88.9) | 13 (54.2) | 0.07 |
*P <0.05